TCM
CLDI icon

Tradewinds Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Tradewinds Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18 Hold
6
– – ﹤0.01% 701
2026
Q1 		$25 Hold
6
– – ﹤0.01% 700
2025
Q4 		$119 Hold
6
– – ﹤0.01% 650
2025
Q3 		$154 Buy
6
+1
+20% +$68 ﹤0.01% 640
2025
Q2 		$230 Hold
5
– – ﹤0.01% 593
2025
Q1 		$567 Hold
5
– – ﹤0.01% 574
2024
Q4 		$1.15K Buy
+5
New +$1.5K ﹤0.01% 535

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Tradewinds Capital Management's CLDI Position: Q2 2026 in Review

Tradewinds Capital Management held its Calidi Biotherapeutics (CLDI) position steady in Q2 2026 at 6 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #701.

Tradewinds Capital Management first reported a position in CLDI in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.15K in Q4 2024. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Tradewinds Capital Management held 6 shares of Calidi Biotherapeutics worth $18 as of Q2 2026.
  • Tradewinds Capital Management left its Calidi Biotherapeutics share count unchanged in Q2 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of Tradewinds Capital Management's portfolio in Q2 2026, its #701 holding.
  • Tradewinds Capital Management first reported a position in Calidi Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • Tradewinds Capital Management's Calidi Biotherapeutics position peaked at $1.15K in Q4 2024.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Tradewinds Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.